Brean Murray disclosed Alder Biopharmaceuticals (NASDAQ:ALDR), hiking its price target to $45.00 earlier today
- Updated: September 29, 2016
Boasting a price of $31.29, Alder Biopharmaceuticals (NASDAQ:ALDR) traded -6.18% lower on the day. With the last stock price close up 12.08% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Alder Biopharmaceuticals has recorded a 50-day average of $32.18 and a two hundred day average of $27.92. Volume of trade was up over the average, with 892,197 shares of ALDR changing hands over the typical 549,722
Indicating a possible upside of 0.44%, Brean Murray bumped up the target price of Alder Biopharmaceuticals (NASDAQ:ALDR) to $45.00
On 9/27/2016, Zacks Investment Research released a statement for Alder Biopharmaceuticals (NASDAQ:ALDR) bumped up the target price from $0.00 to $38.00 that suggested an upside of 0.11%.
With a total market value of $0, Alder Biopharmaceuticals has with a one year low of $15.82 and a one year high of $39.43 .
A total of 4 equity analysts have released a research note on ALDR. Two equity analysts rating the company a strong buy, one equity analyst rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $47.00.
More About Alder Biopharmaceuticals (NASDAQ:ALDR)
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Company's pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company's monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushing's disease. It is also developing ALD403 program for migraine prevention.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.